NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Register

ADVERTISEMENT

ADVERTISEMENT

Recurrence Patterns in High-Risk Resected Melanoma

Sponsored by MSD

Sponsored content is premium paid-for content from commercial clients. The Medical Independent are not involved in the production of this sponsored content.

Resected stage IV melanoma can occur and is high-risk but is not discussed in this material. 

What Is High-Risk Resected Melanoma?1,2

Resected stage IV melanoma can occur and is high risk but is not discussed in this infographic.

Information above is based on AJCC 8th edition clinical staging criteria.

T3a: >2.0–4.0 mm without ulceration; T2b: >1.0–2.0 mm with ulceration; T4a: >4.0 mm without ulceration; T3b: >2.0–4.0 mm with ulceration; T4b: >4.0 mm with ulceration; T: primary tumor; AJCC: American Joint Committee on Cancer; M0: no metastasis


Recurrence Rates for High-Risk Resected Melanoma3,4

* Retrospective review of 738 adult patients from 1993-2013 with stage II resected melanoma. Patients in this study were treated at Memorial Sloan Kettering Cancer Center, New York, NY, North America.


M0: no metastasis, a According to AJCC 7th Edition Staging

† Retrospective chart review of 251 patients from 2011-2016 with stage III resected melanoma followed by watch-and-wait. Patients included in this study were from North America, South America, and Europe.

Median Time to Recurrence in High-Risk Resected Melanoma3,4


M0: no metastasis
a According to AJCC 7th Edition Staging
* Retrospective review of 738 adult patients from 1993-2013 with stage II resected melanoma. Patients in this study were treated at Memorial Sloan Kettering Cancer Center, New York, NY, North America.
† Retrospective chart review of 251 patients from 2011-2016 with stage III resected melanoma followed by watch-and-wait. Patients included in this study were from North America, South America, and Europe.

Patients Often Recurred With Distant Metastases 3,4 




 a According to AJCC 7th Edition Staging 
* Retrospective review of 738 adult patients from 1993-2013 with stage II resected melanoma. Patients in this study were treated at Memorial Sloan Kettering Cancer Center, New York, NY, North America. 
† Retrospective chart review of 251 patients from 2011-2016 with stage III resected melanoma followed by watch-and-wait. Patients included in this study were from North America, South America, and Europe.

References: 

  • 1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: AJCC Cancer Staging Manual. 8th ed. American Joint Committee on Cancer; 2017:563-588. 
  • 2. Helvind NM, et al. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021. JAMA Derm. 2023. doi:10.1001/jamadermatol. 2023.3256 
  • 3. Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939-946. doi:10.1245/s10434-016-5642-0 
  • 4. Mohr P, Kiecker F, Soriano V, et al. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag. 2019;6(4):MMT33. doi:10.2217/mmt-2019-0015 

Category: POM Marketing Authorisation numbers: EU/1/15/1024/002 Marketing Authorisation holder: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands. 

Date of revision: March 2024. 

IE-KEY-00918

© 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. 

All rights reserved. Further information is available on request from: MSD, Red Oak North, South County Business Park, Leopardstown, Dublin D18 X5K7 or from www.medicines.ie. 

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to MSD (Tel: 01-299 8700) 

Please click here to view the KEYTRUDA SPC on medicines.ie

Before prescribing please read the Summary of Product Characteristics for KEYTRUDA available on medicines.ie

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
The Medical Independent 3rd December 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Trending Articles

ADVERTISEMENT